LAWLOR AUGUSTINE
Known title: DirectorCIK: 0001262327
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Gyre Therapeutics Schedules Investor Meetings for September. Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.
Transaction History
| CYPH | ▲ Buy | Option Exercise | 22,500 | — | 3/28/2025 | View on chart |
| CYPH | ▼ Sell | Tax Withholding | 7,797 | $2K | 3/28/2025 | View on chart |
| CYPH | ▼ Sell | Other | 2,136 | $6K | 11/13/2024 | View on chart |
| CYPH | ▲ Buy | Option Exercise | 5,000 | — | 1/26/2024 | View on chart |
| GYRE | ▼ Sell | Other | 24 | — | 8/31/2023 | View on chart |
| GYRE | ▼ Sell | Other | 25 | — | 8/31/2023 | View on chart |
| GYRE | ▲ Buy | Grant | 5,839 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CYPH in Spotlight as Smaller Health Care Names Outperform
Recent coverage noted that smaller health‑care names outperformed larger peers, and CYPH is among those that could benefit from the sector’s momentum. The same report highlighted significant whale activity in health‑care stocks, suggesting growing institutional interest. These developments may affect CYPH’s trading dynamics. No specific price guidance is provided.
CYPH in Spotlight as Smaller Health Care Names Outperform. Recent coverage noted that smaller health‑care names outperformed larger peers, and CYPH is among those that could benefit from the sector’s momentum. The same report highlighted significant whale activity in health‑care stocks, suggesting growing institutional interest. These developments may affect CYPH’s trading dynamics. No specific price guidance is provided.